Literature DB >> 3470047

Pharmacokinetics of imipenem and cilastatin after their simultaneous administration to the elderly.

S Toon, K J Hopkins, F M Garstang, L Aarons, M Rowland.   

Abstract

The pharmacokinetics of imipenem and cilastatin were studied in a group of six healthy elderly male volunteers following the combined intravenous administration of 500 mg imipenem and 500 mg cilastatin sodium as either single or multiple (6 hourly for 6 days) 20 min constant-rate infusions. The pharmacokinetics of both imipenem and cilastatin in the elderly were similar to those of young individuals with mild renal failure (Verpooten et al., 1984). There was no change in the pharmacokinetics of either species with time following multiple-dosing. Correlations existed between total clearance and the glomerular filtration-rate (51Cr-EDTA) for both imipenem and cilastatin.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3470047      PMCID: PMC1386061          DOI: 10.1111/j.1365-2125.1987.tb03022.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  The semi-synthetic thienamycin derivative MK0787 and its properties with respect to a range of beta-lactamases from clinically relevant bacterial species.

Authors:  M H RIchmond
Journal:  J Antimicrob Chemother       Date:  1981-03       Impact factor: 5.790

2.  Determination of imipenem (N-formimidoyl thienamycin) in human plasma and urine by high-performance liquid chromatography, comparison with microbiological methodology and stability.

Authors:  D A Gravallese; D G Musson; L T Pauliukonis; W F Bayne
Journal:  J Chromatogr       Date:  1984-09-14

3.  Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.

Authors:  S R Norrby; K Alestig; B Björnegård; L A Burman; F Ferber; J L Huber; K H Jones; F M Kahan; J S Kahan; H Kropp; M A Meisinger; J G Sundelof
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

4.  The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.

Authors:  G A Verpooten; L Verbist; A P Buntinx; L A Entwistle; K H Jones; M E De Broe
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

5.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

6.  In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin.

Authors:  V W Horadam; J D Smilack; C L Montgomery; J Werringloer
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

7.  Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.

Authors:  H Kropp; J G Sundelof; R Hajdu; F M Kahan
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

  7 in total
  6 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Pharmacokinetics of imipenem in patients undergoing major colon surgery.

Authors:  M Erttmann; R Krausse; U Ullmann
Journal:  Infection       Date:  1990 Nov-Dec       Impact factor: 3.553

3.  Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin.

Authors:  Pratik Bhagunde; Francheska Colon-Gonzalez; Yang Liu; Jin Wu; Shiyao Sherrie Xu; Graigory Garrett; Patricia Jumes; Kenneth Lasseter; Thomas Marbury; Matthew L Rizk; Mallika Lala; Elizabeth G Rhee; Joan R Butterton; Keith Boundy
Journal:  Br J Clin Pharmacol       Date:  2020-01-23       Impact factor: 4.335

Review 4.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage.

Authors:  B R Meyers; P Wilkinson
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

6.  Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants.

Authors:  Elizabeth G Rhee; Matthew L Rizk; Nicole Calder; Marcela Nefliu; Steven J Warrington; Michael S Schwartz; Eric Mangin; Keith Boundy; Pratik Bhagunde; Francheska Colon-Gonzalez; Patricia Jumes; Yang Liu; Joan R Butterton
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.